258
views
0
recommends
+1 Recommend
0 collections
    16
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mutational Processes Molding the Genomes of 21 Breast Cancers

      research-article
      1 , 1 , 1 , 1 , 2 , 3 , 1 , 4 , 5 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 13 , 7 , 7 , 7 , 7 , 8 , 9 , 10 , 11 , 6 , 12 , 13 , 14 , 8 , 9 , 15 , 7 , 16 , 17 , 1 , 1 , 18 , 19 , 1 , , the Breast Cancer Working Group of the International Cancer Genome Consortium
      Cell
      Cell Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          All cancers carry somatic mutations. The patterns of mutation in cancer genomes reflect the DNA damage and repair processes to which cancer cells and their precursors have been exposed. To explore these mechanisms further, we generated catalogs of somatic mutation from 21 breast cancers and applied mathematical methods to extract mutational signatures of the underlying processes. Multiple distinct single- and double-nucleotide substitution signatures were discernible. Cancers with BRCA1 or BRCA2 mutations exhibited a characteristic combination of substitution mutation signatures and a distinctive profile of deletions. Complex relationships between somatic mutation prevalence and transcription were detected. A remarkable phenomenon of localized hypermutation, termed “kataegis,” was observed. Regions of kataegis differed between cancers but usually colocalized with somatic rearrangements. Base substitutions in these regions were almost exclusively of cytosine at TpC dinucleotides. The mechanisms underlying most of these mutational signatures are unknown. However, a role for the APOBEC family of cytidine deaminases is proposed.

          PaperClip

          Abstract

          Graphical Abstract

          Highlights

          ► The genomes of 21 breast cancers sequenced ► Multiple somatic mutational processes extracted from mutation catalogs ► Mutational processes of BRCA1/BRCA2 breast cancers are distinctive ► Localized regions of hypermutation, “kataegis,” are frequent in breast cancers

          Abstract

          Analyses of breast cancer genomes define distinct mutational signatures that imply the existence of multiple distinct somatic mutational processes throughout the genome and reveal a remarkable phenomenon of localized hypermutation. These highly mutated regions vary in size and chromosomal location and are surprisingly frequent in cancer genomes, often colocalizing with somatic rearrangements.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Patterns of somatic mutation in human cancer genomes.

          Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA corresponding to the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern of mutations in individual cancers reflecting different exposures, DNA repair defects and cellular origins. Most somatic mutations are likely to be 'passengers' that do not contribute to oncogenesis. However, there was evidence for 'driver' mutations contributing to the development of the cancers studied in approximately 120 genes. Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

            Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumor progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumor, a brain metastasis, and a xenograft derived from the primary tumor. The metastasis contained two de novo mutations and a large deletion not present in the primary tumor, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumor mutations, and displayed a mutation enrichment pattern that paralleled the metastasis (16 of 20 genes). Two overlapping large deletions, encompassing CTNNA1, were present in all three tumor samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared to the primary tumor suggest that secondary tumors may arise from a minority of cells within the primary.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

              Lay Summary Acute myeloid leukemia is a highly malignant hematopoietic tumor that affects about 13,000 adults yearly in the United States. The treatment of this disease has changed little in the past two decades, since most of the genetic events that initiate the disease remain undiscovered. Whole genome sequencing is now possible at a reasonable cost and timeframe to utilize this approach for unbiased discovery of tumor-specific somatic mutations that alter the protein-coding genes. Here we show the results obtained by sequencing a typical acute myeloid leukemia genome and its matched normal counterpart, obtained from the patient’s skin. We discovered 10 genes with acquired mutations; two were previously described mutations thought to contribute to tumor progression, and 8 were novel mutations present in virtually all tumor cells at presentation and relapse, whose function is not yet known. Our study establishes whole genome sequencing as an unbiased method for discovering initiating mutations in cancer genomes, and for identifying novel genes that may respond to targeted therapies. We used massively parallel sequencing technology to sequence the genomic DNA of tumor and normal skin cells obtained from a patient with a typical presentation of FAB M1 Acute Myeloid Leukemia (AML) with normal cytogenetics. 32.7-fold ‘haploid’ coverage (98 billion bases) was obtained for the tumor genome, and 13.9-fold coverage (41.8 billion bases) was obtained for the normal sample. Of 2,647,695 well-supported Single Nucleotide Variants (SNVs) found in the tumor genome, 2,588,486 (97.7%) also were detected in the patient’s skin genome, limiting the number of variants that required further study. For the purposes of this initial study, we restricted our downstream analysis to the coding sequences of annotated genes: we found only eight heterozygous, non-synonymous somatic SNVs in the entire genome. All were novel, including mutations in protocadherin/cadherin family members (CDH24 and PCLKC), G-protein coupled receptors (GPR123 and EBI2), a protein phosphatase (PTPRT), a potential guanine nucleotide exchange factor (KNDC1), a peptide/drug transporter (SLC15A1), and a glutamate receptor gene (GRINL1B). We also detected previously described, recurrent somatic insertions in the FLT3 and NPM1 genes. Based on deep readcount data, we determined that all of these mutations (except FLT3) were present in nearly all tumor cells at presentation, and again at relapse 11 months later, suggesting that the patient had a single dominant clone containing all of the mutations. These results demonstrate the power of whole genome sequencing to discover novel cancer-associated mutations.
                Bookmark

                Author and article information

                Contributors
                Journal
                Cell
                Cell
                Cell
                Cell Press
                0092-8674
                1097-4172
                25 May 2012
                25 May 2012
                : 149
                : 5-10
                : 979-993
                Affiliations
                [1 ]Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
                [2 ]Center for the Biology of Disease, VIB, Herestraat 49 Box 602, B-3000 Leuven, Belgium
                [3 ]Department of Human Genetics, KU Leuven, Herestraat 49 Box 602, B-3000 Leuven, Belgium
                [4 ]Department of Computing, University of East Anglia, Norwich NR4 7TJ, UK
                [5 ]The Genome Analysis Centre, Norwich Research Park, Norwich NR4 7UH, UK
                [6 ]Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
                [7 ]Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
                [8 ]Faculté de Médecine, INCa-Synergie, Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, France
                [9 ]Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, O310 Oslo, Norway
                [10 ]Breakthrough Breast Cancer Research Unit, Kings College, London SE1 9RT, UK
                [11 ]Department of Medical Oncology, Erasmus Medical Center, Postbus 2040, 3000 CA Rotterdam, The Netherlands
                [12 ]Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada
                [13 ]Department of Oncology, Lund University, BMC C13, SE-221 84 Lund, Sweden
                [14 ]Institut Curie, Departement of Pathology and INSERM U830, 75248 Paris Cedex 05, France
                [15 ]K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo 0310, Norway
                [16 ]Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
                [17 ]MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
                [18 ]Department of Haematology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
                [19 ]Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK
                Author notes
                []Corresponding author mrs@ 123456sanger.ac.uk
                Article
                CELL6267
                10.1016/j.cell.2012.04.024
                3414841
                22608084
                3a204655-3df3-4cd2-8bef-e038e65f8cec
                © 2012 ELL & Excerpta Medica.

                This document may be redistributed and reused, subject to certain conditions.

                History
                : 14 December 2011
                : 12 March 2012
                : 30 April 2012
                Categories
                Article

                Cell biology
                Cell biology

                Comments

                Comment on this article